Login Register Cart 0
Generic placeholder image

Current Drug Delivery

Editor-in-Chief

ISSN (Print): 1567-2018
ISSN (Online): 1875-5704

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Enhanced Oral Bioavailability of Etodolac by the Liquisolid Compact Technique: Optimisation, In-Vitro and In-Vivo Evaluation

Author(s): Bhumin K. Pathak, Meenakshi Raghav, Arti R. Thakkar, Bhavin A. Vyas and Pranav J. Shah*

Volume 18, Issue 4, 2021

Published on: 26 October, 2020

Page: [471 - 486] Pages: 16

DOI: 10.2174/1567201817666201026111559

Price: $65

Abstract

Background: Poor dissolution of Etodolac is one of the major challenges in achieving the desired therapeutic effect in oral therapy.

Objective: This study aimed to assess the potential of the liquisolid compact technique in increasing the rate of dissolution of Etodolac and thus its bioavailability.

Methods: Liquisolid compacts were prepared using PEG 400, Avicel PH-200 and Aerosil 200 as non-volatile liquid, carrier and coating material, respectively. The optimisation was carried out by applying a 32 full factorial design using Design expert software 11.0.3.0 to examine the effects of independent variables (load factor and carrier: coating ratio) on dependent variables (angle of repose and % cumulative drug release at 30 min [Q 30 min]). Assessment of bioavailability was based on a pharmacokinetic study on rabbits and pharmacodynamics evaluation on rats, respectively.

Results: The formulation M3 was identified as the optimised formulation based on the better flow (lower angle of repose) and a higher rate of dissolution (Q 30 min >95%). The higher dissolution rate could be due to conversion of Etodolac into an amorphous molecularly dispersed state, availability of larger surface area, enhancement of aqueous solubility and enhanced wetting of drug particles. Studies with DSC, XRD, and SEM verified the transformation of Etodolac from crystalline to amorphous state, a key factor responsible for improving the dissolution rate. The pharmacokinetic profile of M3 was prominent, demonstrating higher absorption of Etodolac in comparison to oral suspension and immediate-release conventional tablets in rabbits. Liquisolid formulation exhibited a 27% increment in paw thickness as compared to 57% and 46% increments for oral suspension and immediate-release conventional tablets, respectively, after 7 hrs in the carrageenan-induced paw model in rats.

Conclusion: The results indicated the liquisolid compact technique to be a promising strategy to enhance the bioavailability of Etodolac.

Keywords: Immediate release tablet, liquisolid compact technique, dissolution profile, pharmacokinetics, carrageenan-induced paw oedema, capsules.

« Previous Next »
Graphical Abstract

[1]
Wadhwa, J.; Nair, A.; Kumria, R. Emulsion forming drug delivery system for lipophilic drugs. Acta Pol. Pharm., 2012, 69(2), 179-191.
[PMID: 22568032]
[2]
Hart, M.L.; Do, D.P.; Ansari, R.A.; Rizvi, S.A. Brief overview of various approaches to enhance drug solubility. J. Dev. Drugs, 2013, 2(3), 1-7.
[http://dx.doi.org/10.4172/2329-6631.1000115]
[3]
Barakat, N.S. Etodolac-liquid-filled dispersion into hard gelatin capsules: an approach to improve dissolution and stability of etodolac formulation. Drug Dev. Ind. Pharm., 2006, 32(7), 865-876.
[http://dx.doi.org/10.1080/03639040500534192] [PMID: 16908424]
[4]
Brahmankar, D.M.; Jaiswal, S.B. Biopharmaceutics and pharmacokinetics a treatise. Intech, 1995, 117-135.
[5]
Sivert, A.; Bérard, V.; Andrès, C. New binary solid dispersion of indomethacin with surfactant polymer: from physical characterization to in vitro dissolution enhancement. J. Pharm. Sci., 2010, 99(3), 1399-1413.
[http://dx.doi.org/10.1002/jps.21935] [PMID: 19827098]
[6]
Sinha, V.R.; Amita, ; Goel, H. In vivo bioavailability and therapeutic assessment of host-guest inclusion phenomena for the hydrophobic molecule etodolac: pharmacodynamic and pharmacokinetic evaluation. Sci. Pharm., 2010, 78(1), 103-115.
[http://dx.doi.org/10.3797/scipharm.0909-08] [PMID: 21179374]
[7]
MiIic-Askrabic. J.; Rajic, D.S.; Tasic, L.J.; Djuric, S.; Kasa, P.; Pintye-Hodi, K. Etodolac and solid dispersion with p-cyclodextrin. Drug Dev. Ind. Pharm., 1997, 23(11), 1123-1129.
[http://dx.doi.org/10.3109/03639049709150503]
[8]
Modi, A.; Tayade, P. A comparative solubility enhancement profile of valdecoxib with different solubilization approaches. Indian J. Pharm. Sci., 2007, 69(2), 274.
[http://dx.doi.org/10.4103/0250-474X.33156]
[9]
Zhang, Z.L.; Le, Y.; Wang, J.X.; Chen, J.F. Preparation of stable micron-sized crystalline irbesartan particles for the enhancement of dissolution rate. Drug Dev. Ind. Pharm., 2011, 37(11), 1357-1364.
[http://dx.doi.org/10.3109/03639045.2011.575379] [PMID: 21548718]
[10]
Jacob, S.; Nair, A.B. Cyclodextrin complexes: perspective from drug delivery and formulation. Drug Dev. Res., 2018, 79(5), 201-217.
[http://dx.doi.org/10.1002/ddr.21452] [PMID: 30188584]
[11]
Lu, M.; Xing, H.; Jiang, J.; Chen, X.; Yang, T.; Wang, D.; Ding, P. Liquisolid technique and its applications in pharmaceutics. Asian J. Pharm. Sci., 2017, 12(2), 115-123.
[http://dx.doi.org/10.1016/j.ajps.2016.09.007] [PMID: 32104320]
[12]
Spireas, S. Liquisolid systems and methods of preparing same. U.S. patent US6423339B1, 2002, 6, 423-339.
[13]
Vraníková, B.; Gajdziok, J. Liquisolid systems and aspects influencing their research and development. Acta Pharm., 2013, 63(4), 447-465.
[http://dx.doi.org/10.2478/acph-2013-0034] [PMID: 24451071]
[14]
Syed, I.A.; Pavani, E. The liquisolid technique: based drug delivery system. Int. J. Pharm. Sci. Drug Res., 2012, 40(2), 88-96.
[15]
Balfour, J.A.; Buckley, M.M. Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states. Drugs, 1991, 42(2), 274-299.
[http://dx.doi.org/10.2165/00003495-199142020-00008] [PMID: 1717225]
[16]
Okamoto, A.; Shirakawa, T.; Bito, T.; Shigemura, K.; Hamada, K.; Gotoh, A.; Fujisawa, M.; Kawabata, M. Etodolac, a selective cyclooxygenase-2 inhibitor, induces upregulation of E-cadherin and has antitumor effect on human bladder cancer cells in vitro and in vivo. Urology, 2008, 71(1), 156-160.
[http://dx.doi.org/10.1016/j.urology.2007.09.061] [PMID: 18242386]
[17]
Glaser, K.B. Cyclooxygenase selectivity and NSAIDs: cyclooxygenase-2 selectivity of etodolac (Lodine). Inflammopharma- cology, 1995, 3(4), 335-345.
[http://dx.doi.org/10.1007/BF02668029]
[18]
Naito, Y.; Matsuda, H.; Shimomura, K.; Kurihara, K.; Tochigi, K.; Tomono, K. Measurement and correlation of solubilities of the poorly water-soluble pharmaceutical compound etodolac by addition of co-solvents. Fluid Phase Equilib., 2013, 357, 43-49.
[http://dx.doi.org/10.1016/j.fluid.2013.05.025]
[19]
Serajuddin, A.T. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J. Pharm. Sci., 1999, 88(10), 1058-1066.
[http://dx.doi.org/10.1021/js980403l] [PMID: 10514356]
[20]
Afifi, S.; Hassan, M.A.; Abdelhameed, A.S.; Elkhodairy, K.A. Nanosuspension: an emerging trend for bioavailability enhancement of etodolac. Int. J. Polym. Sci., 2015, 2015, 1-16.
[http://dx.doi.org/10.1155/2015/938594]
[21]
Baka, E.; Comer, J.E.; Takács-Novák, K. Study of equilibrium solubility measurement by saturation shake-flask method using hydrochlorothiazide as model compound. J. Pharm. Biomed. Anal., 2008, 46(2), 335-341.
[http://dx.doi.org/10.1016/j.jpba.2007.10.030] [PMID: 18055153]
[22]
Yadav, V.B.; Yadav, A.V. Liquisolid granulation technique for tablet manufacturing: an overview. J. Pharm. Res., 2009, 2(4), 670-674.
[23]
Kumria, R.; Al-Dhubiab, B.E.; Shah, J.; Nair, A.B. Formulation and evaluation of chitosan-based buccal bioadhesive films of zolmitriptan. J. Pharm. Innov., 2018, 13(2), 133-143.
[http://dx.doi.org/10.1007/s12247-018-9312-6]
[24]
Jadhav, N.R.; Irny, P.V.; Patil, U.S. Solid state behavior of progesterone and its release from Neusilin US2 based liquisolid compacts. J. Drug Deliv. Sci. Technol., 2017, 38, 97-106.
[http://dx.doi.org/10.1016/j.jddst.2017.01.009]
[25]
Jacob, S.; Shirwaikar, A.; Nair, A. Preparation and evaluation of fast-disintegrating effervescent tablets of glibenclamide. Drug Dev. Ind. Pharm., 2009, 35(3), 321-328.
[http://dx.doi.org/10.1080/03639040802337021] [PMID: 18821151]
[26]
Shah, R.B.; Tawakkul, M.A.; Khan, M.A. Comparative evaluation of flow for pharmaceutical powders and granules. AAPS PharmSciTech, 2008, 9(1), 250-258.
[http://dx.doi.org/10.1208/s12249-008-9046-8] [PMID: 18446489]
[27]
Govedarica, B.; Injac, R.; Srcic, S. Formulation and evaluation of immediate release tablets with different types of paracetamol powders prepared by direct compression. Afr. J. Pharm. Pharmacol., 2009, 5(1), 31-41.
[http://dx.doi.org/10.5897/AJPP10.274]
[28]
USP 616 Bulk density and tapped density. USP 30 NF, 2007.
[29]
Hausner, H. Friction conditions in a mass of metal powder. Int. J. Powder Metall., 1967, 3, 7-13.
[30]
Carr, R.L. Evaluating flow properties of solids. Chem. Eng., 1965, 18, 163-168.
[31]
Nair, A.B.; Al-Dhubiab, B.E.; Shah, J.; Vimal, P.; Attimarad, M.; Harsha, S. Development and evaluation of palonosetron loaded mucoadhesive buccal films. J. Drug Deliv. Sci. Technol., 2018, 47, 351-358.
[http://dx.doi.org/10.1016/j.jddst.2018.08.014]
[32]
Shah, H.; Nair, A.B.; Shah, J.; Bharadia, P.; Al-Dhubiab, B.E. Proniosomal gel for transdermal delivery of lornoxicam: optimization using factorial design and in vivo evaluation in rats. Daru, 2019, 27(1), 59-70.
[http://dx.doi.org/10.1007/s40199-019-00242-x] [PMID: 30701460]
[33]
Pilli, R.; Nagabhushanam, M.V.; Kadali, S.K. Etodolac dissolution improvement by preparation of solid dispersions with cyclodextrin complexes. Int. J. Pharm. Sci. Res., 2014, 5(11), 4774-4791.
[34]
Shaikh, F.A.; Mantry, S. Formulation and evaluation of tenofoir disoproxil fumarate immediate release tablets. Int. J. Pharm. Sci. Res., 2013, 1(2), 252-265.
[35]
Lachman, L.; Liberman, H.A.; Kaing, J.L. Theory and practice of industrial pharmacy. Especial Indian Ed., 2009.
[36]
Abd-Elbary, A.; Tadros, M.I.; Alaa-Eldin, A.A. Development and in vitro/in vivo evaluation of etodolac controlled porosity osmotic pump tablets. AAPS PharmSciTech, 2011, 12(2), 485-495.
[http://dx.doi.org/10.1208/s12249-011-9608-z] [PMID: 21479749]
[37]
Insuyu, P.D.; Atila, A.; Kadioglu, Y.; Turan, A. Quantitative determination of etodolac by UV spectrophotometric method in bulk drug and commercial formulations. Int. J. Pharm. Sci. Res., 2013, 4(8), 2927-2932.
[38]
Ficarra, R.; Ficarra, P.; Calabro, M.; Costantino, D. Quantitative high-performance liquid chromatographic determination in pharmaceutical formulations. IL Farmaco, 1991, 46, 403-407.
[39]
Spireas, S.; Sadu, S. Enhancement of prednisolone dissolution properties using liquisolid compacts. Int. J. Pharm., 1998, 166(2), 177-188.
[http://dx.doi.org/10.1016/S0378-5173(98)00046-5]
[40]
Spireas, S.S.; Jarowski, C.I.; Rohera, B.D. Powdered solution technology: principles and mechanism. Pharm. Res., 1992, 9(10), 1351-1358.
[http://dx.doi.org/10.1023/A:1015877905988] [PMID: 1448438]
[41]
Spireas, S.S. Theoretical and Practical Aspects of liquisolid compacts ; , 1993.
[42]
Chella, N.; Shastri, N.; Tadikonda, R.R. Use of the liquisolid compact technique for improvement of the dissolution rate of valsartan. Acta Pharm. Sin. B, 2012, 2(5), 502-508.
[http://dx.doi.org/10.1016/j.apsb.2012.07.005]
[43]
Jhaveri, M.; Nair, A.B.; Shah, J.; Jacob, S.; Patel, V.; Mehta, T. Improvement of oral bioavailability of carvedilol by liquisolid compact: optimization and pharmacokinetic study. Drug Deliv. Transl. Res., 2020, 10(4), 975-985.
[http://dx.doi.org/10.1007/s13346-020-00734-3] [PMID: 32124413]
[44]
Sherje, A.; Londhe, V. Inclusion complexes of hydroxy propyl-β- cyclodextrin and paliperidone: preparation and characterization. Curr. Drug Discov. Technol., 2014, 11(4), 271-278.
[http://dx.doi.org/10.2174/1570163812666150109103618] [PMID: 25578059]
[45]
Sayyad, F.; Tulsankar, S.L.; Kolap, U.B. Design and development of liquisolid compact of candesartan cilexetil to enhance dissolution. J. Pharm. Res., 2013, 7(5), 381-388.
[http://dx.doi.org/10.1016/j.jopr.2013.05.012]
[46]
Vittal, G.V.; Deveswaran, R.; Bharath, S.; Basavaraj, B.; Madhavan, V. Formulation and characterization of ketoprofen liquisolid compacts by Box-Behnken design. Int. J. Pharm. Investig., 2012, 2(3), 150-156.
[http://dx.doi.org/10.4103/2230-973X.104398] [PMID: 23373006]
[47]
Spireas, S.; Sadu, S.; Grover, R. In vitro release evaluation of hydrocortisone liquisolid tablets. J. Pharm. Sci., 1998, 87(7), 867-872.
[http://dx.doi.org/10.1021/js970346g] [PMID: 9649356]
[48]
Petrovick, P.R.; Jacob, M.; Gaudy, D.; Bassani, V.L.; Guterres, S.S. Influence of adjuvants on the in vitro dissolution of hydrochlorothiazide from hard gelatin capsules. Int. J. Pharm., 1991, 76(1-2), 49-53.
[http://dx.doi.org/10.1016/0378-5173(91)90342-L]
[49]
Patel, N.K.; Upadhyay, A.H.; Bergum, J.S.; Reier, G.E. An evaluation of microcrystalline cellulose and lactose excipients using an instrumented single station tablet press. Int. J. Pharm., 1994, 110(3), 203-210.
[http://dx.doi.org/10.1016/0378-5173(94)90242-9]
[50]
Vaishnani, R.; Nataranjan, R.; Rajendran, N.N. Formulation and evaluation of immediate release tablets of paroxetine HCl using different super disintegrants. J. Pharm. Res., 2011, 2(3), 1095-1099.
[51]
Barakat, N.S. Enhanced oral bioavailability of etodolac by self-emulsifying systems: in-vitro and in-vivo evaluation. J. Pharm. Pharmacol., 2010, 62(2), 173-180.
[http://dx.doi.org/10.1211/jpp.62.02.0004] [PMID: 20487196]
[52]
Srinath, P.; Diwan, P.V. Pharmacodynamic and pharmacokinetic evaluation of lipid microspheres of indomethacin. Pharm. Acta Helv., 1998, 73(4), 199-203.
[http://dx.doi.org/10.1016/S0031-6865(98)00023-5] [PMID: 9861868]

Rights & Permissions Print Cite
Article Metrics
16
1
© 2024 Bentham Science Publishers | Privacy Policy